Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 1/47 5/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48 | Neoplastic Lesions |
| Yes | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Heart | Clear Evidence | Clear Evidence | schwannoma malignant (0/90, 2/90, 3/90, 6/90) | Neoplastic Lesions |
| Yes | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Heart | Clear Evidence | Clear Evidence | schwannoma malignant (0/90, 2/90, 1/90, 5/90) | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 1/48 2/48 3/48 4/48 6/48 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant schwannoma 2/48 3/48 3/48 7/47 8/48 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 2/48 1/48 0/48 2/48 4/48 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 1/4 6/48 12/47 3/48 8/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 4/46 0/46 2/48 5/45 8/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 0/45 8/44 20/48 32/47 31/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 2/48 1/48 0/48 2/48 4/48 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 1/48 2/48 3/48 4/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 1/48 3/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 18/48 24/46 22/47 31/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Pancreas Islet Cell | Clear Evidence | Clear Evidence | adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 1/48 2/48 1/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48 | Neoplastic Lesions |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Adrenal Gland Medulla | Equivocal Evidence | Equivocal Evidence | benign, malignant, or complex pheochromocytoma (1/86, 9/89, 5/87, 4/88) | May Have Been Related |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Brain | Equivocal Evidence | Equivocal Evidence | glioma malignant (0/90, 3/90, 0/90, 0/90) | May Have Been Related |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Clear Evidence | glioma malignant (0/90, 0/90, 0/90, 3/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Heart | Equivocal Evidence | Equivocal Evidence | schwannoma malignant (0/90, 2/90, 0/90, 2/90) | May Have Been Related |
| Yes | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Heart | Clear Evidence | Clear Evidence | schwannoma malignant (0/90, 2/90, 3/90, 6/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Liver | Clear Evidence | Equivocal Evidence | hepatocellular adenoma or carcinoma (combined) (0/90, 2/90, 4/89, 1/88) | May Have Been Related |
| No | TR-595 | CELLPRADCDMA | Cell Phone Radiation: CDMA | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Pituitary Gland | Clear Evidence | Equivocal Evidence | pars distalis, adenoma (17/89, 25/90, 34/90, 13/90) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | benign, malignant, or complex pheochromocytoma (11/88, 24/90, 28/89, 14/87) | Neoplastic Lesions |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Equivocal Evidence | meninges, granular cell tumor benign or malignant (1/90, 3/90, 4/90, 3/90) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Brain | Clear Evidence | Clear Evidence | glioma malignant (0/90, 3/90, 3/90, 2/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Female | Whole Body Exposure | Heart | Equivocal Evidence | Equivocal Evidence | schwannoma malignant (0/90, 0/90, 2/90, 0/90) | May Have Been Related |
| Yes | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Heart | Clear Evidence | Clear Evidence | schwannoma malignant (0/90, 2/90, 1/90, 5/90) | Neoplastic Lesions |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Pancreas Islet Cell | Clear Evidence | Equivocal Evidence | adenoma or carcinoma (13/90, 27/89, 19/86, 16/85) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Pituitary Gland | Clear Evidence | Equivocal Evidence | pars distalis, adenoma (17/89, 28/90, 26/90, 26/90) | May Have Been Related |
| No | TR-595 | CELLPRADGSM | Cell Phone Radiation: GSM | Rats | Hsd:Sprague Dawley SD | Male | Whole Body Exposure | Prostate Gland | Clear Evidence | Equivocal Evidence | adenoma or carcinoma (2/90, 2/90, 7/90, 3/90) | May Have Been Related |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Rats | Sprague Dawley | Female | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Rats | Sprague Dawley | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-059 | 22966-79-6 | Estradiol mustard | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Female | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Male | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | All Organs | Clear Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 4/48 6/48 7/48 11/48 14/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/45 3/48 10/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/48 3/48 10/47 17/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 1/45 1/45 1/47 5/45 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/48 1/48 0/48 0/47 3/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/45 19/47 20/47 24/46 40/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 3/47 17/47 23/47 32/46 42/47 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant schwannoma 2/48 3/48 3/48 7/47 8/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 26/48 35/48 33/48 36/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Equivocal Evidence | granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/47 3/48 6/47 13/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46 | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 1/47 5/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 0/46 2/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/45 1/47 4/46 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 0/48 2/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46 | Neoplastic Lesions |